Evaxion Biotech A/S (NASDAQ:EVAX) Short Interest Update

Evaxion Biotech A/S (NASDAQ:EVAX) was the target of a large growth in short interest in the month of December. As of December 15th, there was short interest totalling 121,100 shares, a growth of 285.7% from the November 30th total of 31,400 shares. Based on an average daily trading volume, of 61,300 shares, the short-interest ratio is presently 2.0 days.

Evaxion Biotech A/S Stock Up 25.3 %

Shares of NASDAQ:EVAX traded up $0.21 during trading on Friday, hitting $1.06. The stock had a trading volume of 8,476,896 shares, compared to its average volume of 267,984. The company has a quick ratio of 2.80, a current ratio of 1.00 and a debt-to-equity ratio of 7.99. The company has a market capitalization of $6.22 million, a PE ratio of -3.66 and a beta of -0.39. The firm’s fifty day moving average is $1.76 and its 200 day moving average is $2.55. Evaxion Biotech A/S has a 12 month low of $0.84 and a 12 month high of $13.61.

Evaxion Biotech A/S (NASDAQ:EVAX) last issued its quarterly earnings results on Thursday, October 31st. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.08. The business had revenue of $3.02 million during the quarter, compared to the consensus estimate of $0.19 million. Analysts anticipate that Evaxion Biotech A/S will post -0.15 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Evaxion Biotech A/S in a report on Friday, November 1st.

Institutional Trading of Evaxion Biotech A/S

An institutional investor recently bought a new position in Evaxion Biotech A/S stock. Invst LLC acquired a new stake in shares of Evaxion Biotech A/S (NASDAQ:EVAX) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 54,000 shares of the company’s stock, valued at approximately $156,000. Invst LLC owned about 1.00% of Evaxion Biotech A/S at the end of the most recent quarter. 11.04% of the stock is currently owned by hedge funds and other institutional investors.

Evaxion Biotech A/S Company Profile

Evaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers.